CYP4F12

From Wikipedia, the free encyclopedia
Jump to: navigation, search
CYP4F12
Identifiers
Aliases CYP4F12, CYPIVF12, F22329_1, cytochrome P450 family 4 subfamily F member 12
External IDs MGI: 1927669 HomoloGene: 81872 GeneCards: 66002
RNA expression pattern
PBB GE CYP4F12 206539 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_023944

NM_001204333
NM_001204334
NM_001204335
NM_001204336
NM_022434

RefSeq (protein)

NP_076433.3

NP_001191262.1
NP_001191263.1
NP_001191264.1
NP_001191265.1
NP_071879.1

Location (UCSC) Chr 19: 15.67 – 15.7 Mb Chr 17: 32.91 – 32.92 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

Cytochrome P450 4F12 is a protein that in humans is encoded by the CYP4F12 gene.[1][2]

This gene encodes a member of the cytochrome P450 superfamily of enzymes and is part of a cluster of cytochrome P450 genes on chromosome 19.[2][3] The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein likely localizes to the endoplasmic reticulum. CYP4F12 is expressed in the liver and throughout the gastrointestinal track, is known to metabolize the anti-histamine drugs, ebastine and terfenadine, and therefore is suggested to be positioned for and possibly involved in the processing of these and perhaps other drugs.[3][4]

When expressed in yeast the enzyme is capable of oxidizing arachidonic acid by adding a hydroxyl residue to carbons 18 or 19 to form 18-hydroxyeicosatetraenoic acid (18-HETE) or 19-HETE; however, its physiological function in doing so has not been determined. CYP4F12 also metabolizes prostaglandin H2 (PGH2) and PGH1 to their corresponding 19-hydroxyl analogs in a reaction that might serve to reduce their activities.[5] In addition to these monooxygenase actions, CYP458 possesses epoxygenase activity: it metabolizes the omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid, (EPA) to their corresponding epoxides, the epoxydocosapentaenoic acids (EDPs) and epoxyeicosatetraenoic acids (EEQs), respectively.[6] The enzyme metabolizes DHA primarily to 19R,20S-epoxyeicosapentaenoic acid and 19S,20R-epoxyeicosapentaenoic acid isomers (termed 19,20-EDP) and EPA primarily to 17R,18S-eicosatetraenic acid and 17S,18R-eicosatetraenic acid isomers (termed 17,18-EEQ).[6] 19-HETE is an inhibitor of 20-HETE, a broadly active signaling molecule which acts to onstrict arterioles, elevate blood pressure, promote inflammation responses, and stimulates the growth of various types of tumor cells; however the in vivo ability and significance of 19-HETE in inhibiting 20-HETE has not been demonstrated (see 20-Hydroxyeicosatetraenoic acid). The EDPs (see Epoxydocosapentaenoic acid) and EEQs (see epoxyeicosatetraenoic acid) have a broad range of activities. In various animal models and in vitro studies on animal and human tissues, they decrease hypertension and pain perception; suppress inflammation; inhibit angiogenesis, endothelial cell migration and endothelial cell proliferation; and inhibit the growth and metastasis of human breast and prostate cancer cell lines.[7][8][9][10] It is suggested that the EDP and EEQ metabolites function in humans as they do in animal models and that, as products of the omega-3 fatty acids, DHA acid and EPA, the EDP and EEQ metabolites contribute to many of the beneficial effects attributed to dietary omega-3 fatty acids.[7][10][11] EDP and EEQ metabolites are short-lived, being inactivated within seconds or minutes of formation by epoxide hydrolases, particularly soluble epoxide hydrolase, and therefore act locally.

The fatty acid metabolizing activity, including the ability to form epoxides, of CYP4F12 is very similar to that of CYP4F8. However, it and CYP4F8 are not regarded as being major contributors in forming the cited epoxides in humans although they might do so in tissues where they are highly expressed.[5]

References[edit]

  1. ^ Bylund J, Bylund M, Oliw EH (Feb 2001). "cDna cloning and expression of CYP4F12, a novel human cytochrome P450". Biochem Biophys Res Commun 280 (3): 892–7. doi:10.1006/bbrc.2000.4191. PMID 11162607. 
  2. ^ a b "Entrez Gene: CYP4F12 cytochrome P450, family 4, subfamily F, polypeptide 12". 
  3. ^ a b Stark, Katarina; Wongsud, Buanus; Burman, Robert; Oliw, Ernst H. (15 September 2005). "Oxygenation of polyunsaturated long chain fatty acids by recombinant CYP4F8 and CYP4F12 and catalytic importance of Tyr-125 and Gly-328 of CYP4F8". Archives of Biochemistry and Biophysics 441 (2): 174–181. doi:10.1016/j.abb.2005.07.003. ISSN 0003-9861. PMID 16112640. 
  4. ^ Johnson, Amanda L.; Edson, Katheryne Z.; Totah, Rheem A.; Rettie, Allan E. (1 January 2015). "Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer". Advances in Pharmacology (San Diego, Calif.) 74: 223–262. doi:10.1016/bs.apha.2015.05.002. ISSN 1557-8925. PMID 26233909. 
  5. ^ a b Johnson AL, Edson KZ, Totah RA, Rettie AE (2015). "Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer". Advances in Pharmacology 74: 223–62. doi:10.1016/bs.apha.2015.05.002. PMID 26233909. 
  6. ^ a b Westphal C, Konkel A, Schunck WH (November 2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators 96 (1-4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID 21945326. 
  7. ^ a b Fleming I (October 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID 25244930. 
  8. ^ Zhang G, Kodani S, Hammock BD (January 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer". Progress in Lipid Research 53: 108–23. doi:10.1016/j.plipres.2013.11.003. PMID 24345640. 
  9. ^ He J, Wang C, Zhu Y, Ai D (December 2015). "Soluble epoxide hydrolase: A potential target for metabolic diseases". Journal of Diabetes. doi:10.1111/1753-0407.12358. PMID 26621325. 
  10. ^ a b Wagner K, Vito S, Inceoglu B, Hammock BD (October 2014). "The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling". Prostaglandins & Other Lipid Mediators. 113-115: 2–12. doi:10.1016/j.prostaglandins.2014.09.001. PMID 25240260. 
  11. ^ Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, Dechend R, Muller DN, Rothe M, Luft FC, Weylandt K, Schunck WH (March 2014). "Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway". Journal of Lipid Research 55 (6): 1150–1164. doi:10.1194/jlr.M047357. PMID 24634501. 

Further reading[edit]